Our vision for research transparency is that trusted information from health and social care research studies is publicly available for the benefit of all.
All research should be registered in a publicly accessible database. For clinical trials, it is a condition of a favourable ethics opinion. Following a favourable opinion from a Research Ethics Committee (REC), the sponsor should register the study on a World Health Organisation (WHO) compliant registry before the first participant is recruited, and no later than six weeks after.
It is recommended that researchers use either the UK-based registry ISRCTN or the US-based registry ClinicalTrials.gov. These registries feed in to ‘Be Part of Research', an online service run by the National Institute for Health and Care Research (NIHR), which helps members of the public understand what research is, what it might mean to take part, and shows what research is currently happening across the UK.
Last year, we published, for the first time, a full list of clinical trials that had received a favourable opinion from a REC in 2022, with the registration details that we hold for them.
This year, as part of our commitment to publish transparency performance in the research community, we are publishing a full list of clinical trials that received a favourable opinion from a REC in 2023, with the registration details we hold for them. We are publishing the full list in a csv file.
We are also publishing a table of clinical trials which were given a favourable opinion from a REC in 2023 which we have not received a registration number for. The table contains data we held in March 2025. Updates after this date will be appear on the research summaries webpage. This one remains a snapshot of the position this week.
What we are publishing
We are sharing data on the registration status of clinical trials in the UK that received a favourable opinion from RECs in 2023, including their registration number or an explanation for non-registration where this is known.
Clinical trials are defined as:
- clinical trial of an investigational medicinal product
- clinical investigation or other study of a medical device
- combined trial of an investigational medicinal product and an investigational medical device
- other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice
Please note that in our data published values have been rounded and may not add up to 100%.
A number of changes have been made to the way we collect data from last year:
- we did not conduct an internet search for missing registration numbers
- since the last report was published, we have started actively contacting sponsors one year after they received a REC favourable opinion to check if they have registered their study. This is to encourage awareness of the expectation to register their trial, promote transparency among researchers and sponsors, and ensure our data is accurate
- we no longer accept listing on EudraCT as meeting the condition for registration, as it does not support visibility of UK trials
What we found
At the time of publication of this report 91% of clinical trials that received a favourable opinion from a UK REC in 2023 have provided the HRA with a registration number, with a further 1% in the process of registering. 4% of clinical trials have not provided the HRA with a registration number and the sponsor has not told us why.
There have been a number of changes in how the data was compiled for last year’s Clinical trial registration report 2022.
Last year 92% were registered, or in the process of registering, but if we take out those that had a listing on EudraCT and registration numbers obtained through an internet search it is 84%.
The number of studies where we hold a registration number without having conducted an internet search or being listed on EudraCT has increased by 7% from 84% of studies approved 2022 to 92% of studies approved 2023.
There is also a reduction in the studies not registered with no reason provided from 10% in 2022 to 4% in 2023.
The most popular registry used for clinical trials given a favourable opinion in 2023 was ClinicalTrials.gov, which is the same as 2022.
Fewer sponsors used ISRCTN and other WHO recognised registries in comparison to 2022.
However, more sponsors had used a registry that supported visibility of UK trials as listing the study on EudraCT was no longer considered registration.
Of the 4% who have provided a reason for non-registration, the most common explanation was that the study had not started because recruitment had not yet begun or the study had been withdrawn. There were also a significant number of sponsors who no longer considered their study to be a clinical trial.
This year, for the first time, we compared the registration status of CTIMPs and non-CTIMPs. This show that registration compliance is higher for CTIMPs than non-CTIMPs.
We also compared registration status for commercial and non-commercial studies for the first time. This found that registration compliance is higher for commercially sponsored clinical trials than non-commercially sponsored trials.
Registration data
The below table sets out clinical trials which were given a favourable opinion from a REC in 2023 which we have not received a registration number for.
Where a reason for non-registration was provided at the point the study was contacted 12 months after receiving REC approval, this has been included.
If your study is on this list and you would like to inform us of the registration number please email us at deferrals@hra.nhs.uk and this will appear on the research summaries webpage.
The studies are arranged in order of IRAS number. This is a number given to a study when the first application for approvals is made and which follows the study through its lifecycle, until the results are published.
The full registration data set of clinical trials that received a favourable opinion from a REC in 2023 is available as a CSV file. There is not one single registry for clinical trials. The format of the number in the csv.file can tell you which register the study has used.
ISRCTN - Numbers beginning ISRCTN
Clinicaltrials.gov - Numbers beginning NCT
ANZCTR - Numbers beginning ACTRN
| IRAS project ID | Full research title | Sponsor organisation | Reason for non-registration |
| 287382 |
Comparison of the response of Cardiac Resynchronisation Therapy (CRT) using high frequency ECG or Q-LV measurement guided optimisation for left ventricular pacing site |
University Hospitals Birmingham | |
| 290017 |
The development of a self-ASSESSment decision aid to enable people with haemophilia (PWH) to detect and manage acute musculoskeletal bleeding events utilising ultrasound technology (ASSESS) |
Canterbury Christ Church University |
Sponsor no longer considers study a Clinical Trial |
| 293226 |
Advanced imaging techniques for head and neck cancer to stratify risk of early treatment failure |
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge |
|
| 298941 |
Novel Magnetic Resonance Imaging for Diagnosing Obstetric Brachial Plexus Injuries: A Pilot Proof of Concept Study |
Leeds Teaching Hospitals NHS Trust |
Sponsor no longer considers study a Clinical Trial |
| 299758 |
A randomised trial assessing recurrence of periodontal disease during orthodontic treatment in patients following successful periodontal treatment |
King's College London | Recruitment not yet started |
| 306353 |
Context- and Terrain-Aware Gait Analysis and Visualisation |
University of Leeds | |
| 306813 |
Does NTproBNP point of care testing on admission to hospital improve clinical outcomes for newly suspected heart failure patients? A feasibility quantitative study |
Stirling University | |
| 309977 |
Memokath 051 Double cone metallic stents in treating intractable ureteric obstruction |
South Tees Hospitals NHS Foundation Trust | Recruitment not yet started |
| 311815 |
A digital approach to grief support and post-loss mental health problems |
University of Oxford | Recruitment not yet started |
| 312391 |
Partial Volume high-dose Irradiation in Renal Cell Carcinoma for intra-TUmoural control ALongside current management (VIRTUAL) - a randomised feasibility study |
Royal Marsden Hospital | |
| 315702 |
Optical Technologies for the Detection of Respiratory Infection in the Intensive Care Unit |
University of Edinburgh | Recruitment not yet started |
| 315717 |
Targeted perfusion based haemodynamic management in critically ill patients using urethral perfusion – a pilot study |
King's College Hospital NHS Foundation Trust |
|
| 316094 |
Adaptive Interaction for relationships: the impact of Adaptive Interaction training on enabling relationships and enhancing the human rights of individuals with advanced dementia via social interaction |
University of St Andrews |
Sponsor no longer considers study a Clinical Trial |
| 316602 |
A Double-Blind Randomised Multi-Centre Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ethyl Lauroyl Arginate Hydrochloride (ELAH) Formulation Versus a Matching Placebo Formulation in Terms of Effective Prevention from SARS-CoV-2 and Other Respiratory Viruses including H1N1 Influenza and Human RSV |
Salvacion USA Inc | Recruitment not yet started |
| 316674 |
A prospective observational study surveying the impact of utilising Contrelle Activgard in women with incontinence on quality of life |
University Hospital Southampton NHS Foundation Trust |
Recruitment not yet started |
| 316706 |
Exploring the use of a positive mental imagery intervention for targeting suicidal ideation in psychosis |
Lancaster University |
Sponsor no longer considers study a Clinical Trial |
| 317895 |
An exercise and nutrition intervention for locally advanced prostate cancer patients starting Androgen Deprivation Therapy |
University of Hull | Recruitment not yet started |
| 318366 |
An at-home exercise programme for metastatic prostate cancer patients: a feasibility trial |
University of Hull | Recruitment not yet started |
| 319064 |
A cognitive behavioural intervention to improve self-esteem in sexual minority women in primary care psychological therapies services: a feasibility and acceptability study |
Kings College London |
Sponsor no longer considers study a Clinical Trial |
| 319270 |
A blended intervention for depression after acquired brain injury using a novel smartphone-based application: a feasibility and acceptability investigation |
IoPPN Kings College London University | |
| 319521 |
Study to investigate intra-uterine temperature and intra-uterine oxygen levels and the impact of sildenafil |
Verso Biosense | |
| 319893 |
Transcutaneous spinal cord stimulation for enhanced upper limb rehabilitation in acute spinal cord injury |
Royal National Orthopaedic Hospital | |
| 319928 |
Post market surveillance study to confirm the ongoing safety and performance of Silver I Alginate Non-Woven Dressing (Hydro-Alginate) in chronic and acute wounds |
Advanced Medical Solutions Limited. | |
| 320697 |
Simultaneous Endo-Epicardial Mapping of Recurrent Atrial Fibrillation 2 |
Brighton and Sussex University Hospitals NHS Trust |
|
| 321104 |
Predictive appRroaches in managing peOple with long-TErm Conditions at risk of demenTia : from remote monitoring data to digital biomarkers |
Surrey and Borders Partnership NHS Foundation Trust |
|
| 321287 |
Walk with path feasibility and product assessment of ‘Path Insight’ (PIN) in arthroplasty patients. |
Imperial College London |
Sponsor no longer considers study a Clinical Trial |
| 321754 |
CardiopuLmonary function testing in the Emergency general Surgical Setting: A LESS invasive method of measuring fitness |
ST James's University Hospital | Recruitment not yet started |
| 321992 |
Multicenter glaucoma study investigating standalone canaloplasty (MAGIC) |
Nova Eye Medical | |
| 322394 |
Adaptation and evaluation of the Enhancing Parenting Skills programme for use in a neurodevelopmental service |
Bangor University | Recruitment not yet started |
| 322904 |
A feasibility study to evaluate the treatment of chronic abdominal pain patients using objective evoked compound action potentials (ECAPs) |
Leeds Teaching Hospitals NHS Trust | |
| 322939 |
Clinical Performance Study Establishing Reference Intervals for CoaguScan System |
Highland Biosciences Limited | |
| 323051 |
HeteroGenius Skin Cancer AI Pathology Assistant: Usability Testing Study |
University of Bradford |
Sponsor no longer considers study a Clinical Trial |
| 323712 |
Electroencephalogram (EEG) after traumatic brain injury in a critical care setting using a novel dry in-ear EEG compared to current practice using scalp EEG |
Imperial College London | Recruitment not yet started |
| 324099 |
A study of in-ear electroencephalography signals additionally recorded in hospitalised patients already undergoing standard clinical electroencephalography |
Imperial College London | |
| 324194 |
GestaTIonal TrophoblAstic NeoplasIa Ultrasound assessMent: TITANIUM study |
Imperial College London | Recruitment not yet started |
| 324413 |
MediMusic real world validation for pain and medication self-management in patients with chronic musculoskeletal conditions |
Lancashire Teaching Hospitals NHS Foundation Trust |
Recruitment not yet started |
| 324422 |
Ear Nose & Throat (ENT) Product Surveillance Registry (PSR) platform base clinical investigation plan PROPEL Drug-Eluting Sinus Stent Family Addendum |
Medtronic Inc. | |
| 325061 |
Prospective open-label single site pilot study to assess the effects of spinal cord stimulation on autonomic function in patients with post-chemotherapy and post-radiation cancer-related pain |
Leeds Teaching Hospitals NHS Trust |
Sponsor no longer considers study a Clinical Trial |
| 325200 |
The value of eye tracking in the management of different types of neurodegenerative disease |
University of Bristol |
Sponsor no longer considers study a Clinical Trial |
| 325511 |
Performance and Usability Evaluation of OrientGene 5 in 1 SARS-CoV-2 influenza A influenza B Respiratory Syncytial Virus (RSV) and Adenovirus (ADV) Antigen Self-Test (product code: GCFCRA-T525a) Performance and Usability Evaluation |
Accubio | Recruitment not yet started |
| 325549 |
Narrative-Mantra Multi-family Group for Families Awaiting Treatment at the Bromley Child and Adolescent Mental Health Service (CAMHS) in London UK |
Oxleas NHS Foundation Trust | Recruitment not yet started |
| 325686 |
Improving the Management and Prevention of Perineal Wound Dehiscence from Episiotomies using Flaminal: A Pilot Study |
Gloucestershire Royal Hospital | Recruitment not yet started |
| 325879 |
Verifying the effect of DOAC stop on plasma where there is a need to rule in/out causes of prolongation in coagulation screen results |
Blackpool Teaching Hospitals NHS Foundation Trust |
Sponsor no longer considers study a Clinical Trial |
| 326238 |
Feasibility and acceptability of using VIPP in perinatal services |
University of Surrey |
Sponsor no longer considers study a Clinical Trial |
| 326369 |
Can user-centred design and behavioural-science informed interventions improve equity in outpatient access in North West London? A non-randomised controlled trial |
Imperial College London | |
| 326461 |
CO2 versus air insufflation in children undergoing Percutaneous Endoscopic Gastrostomy (PEG) |
Sheffield Children's Hospital NHS Trust | |
| 326527 |
Optimizing prehabilitation exercise to enhance tumour outcomes in advanced oesophageal cancer |
University of Surrey | |
| 326625 |
Investigating gut hormone levels in colonic motility GutCM |
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge |
Recruitment not yet started |
| 327020 |
Virtual reality and its use in reducing Perioperative Stress in Cataract Surgery |
South Tyneside and Sunderland NHS foundation Trust |
|
| 327079 |
CP348 - A randomized open-labelled crossover study confirming performance of a new single-use compact intermittent catheter in a population of adult female intermittent catheter users |
Coloplast A/S | |
| 328072 |
A Time and Cost Savings Analysis of an AI Pathology Assistant |
University of Bradford |
Sponsor no longer considers study a Clinical Trial |
| 328073 |
Evaluation of a novel suprasternal Doppler probe for hemodynamic assessment in the critically ill |
Deltex Medical Limited | Recruitment not yet started |
| 328108 |
Treatment Engagement and Quality of Life in Psychosis: A Feasibility Study of an Adapted Individual Mindfulness-Based Intervention |
University of Edinburgh | Recruitment not yet started |
| 330188 |
Feasibility study of chest drain insertion and talc pleurodesis for malignant pleural effusion on an ambulatory basis |
NHS North Tees and Hartlepool foundation Trust |
|
| 330766 |
The impact of low-energy totAl diet Replacement with behavioural support for remIssion of type 2 DIAbetes on disordEred eatiNg: the ARIADNE randomised non-inferiority controlled trial |
University of Oxford | |
| 333250 |
The Broad-Minded Affective Coping Strategy in Bipolar Disorder: A single-arm pre-post pilot study |
Lancashire & South Cumbria NHS Foundation Trust |
Sponsor no longer considers study a Clinical Trial |
| 334487 |
Usability and acceptability of a nurse-led weight talk tool: A think-aloud study at inpatient adult secure mental health unit |
University of Surrey |
Sponsor no longer considers study a Clinical Trial |
| 1004300 |
Assessment of safety and efficacy of subcutaneous remternetug in early symptomatic Alzheimer’s disease |
Ellipses Pharma Limited | |
| 1004758 |
A participant- and investigator-blinded randomized placebo-controlled multicenter platform study to investigate efficacy safety and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis |
Novartis Pharma AG | |
| 1004950 |
Evaluating the effects of GLP-1 analogue oral semaglutide in Alzheimer's disease |
Imperial College London | Recruitment not yet started |
| 1005368 |
Reirradiation (re-RT) and Niraparib (NIRA) in patients with recurrent Glioblastoma (rGBM) |
University College London | Recruitment not yet started |
| 1005996 |
A Phase 2a Randomized Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Patients with Sickle Cell Disease |
Alexion Pharmaceuticals Inc | Recruitment not yet started |
| 1006142 |
A multicenter randomized double-blind placebo-controlled parallel-group phase 3 study to evaluate the safety and efficacy of masitinib as add-on therapy in patients with mild to moderate Alzheimer's disease treated with standard of care: cholinesterase inhibitors memantine |
AB Science | |
| 1006384 |
A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The EvolvE Study) |
Celldex Therapeutics Inc. | |
| 1006395 |
A Phase 2a Multiple Ascending Dose Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of PK-051 (Combination of Fluphenazine and Trimipramine) in Patients with Mild Cognitive Impairment |
PharmaKure Ltd | Recruitment not yet started |
| 1006492 |
A Phase 3b Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 mg in Adults Who Have Obesity or Overweight with Weight-Related Comorbidities (SURMOUNT-5) |
Eli Lilly and Company | |
| 1006557 |
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma |
Takeda Development Center Americas Inc. | Recruitment not yet started |
| 1006595 |
A phase 3 randomized double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or relapsed after first line steroid treatment (VAYHIT2) |
Novartis Pharma AG | |
| 1006645 |
FARGO: A randomised phase IIa multi-centre placebo-controlled trial of FAecal microbiota transplantation in primaRy sclerosinG chOlangitis |
University of Birmingham | |
| 1006706 |
A Phase 1/2a Open-label Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With Relapsed or Refractory Multiple Myeloma |
Takeda Development Center Americas Inc. | Recruitment not yet started |
| 1006719 |
A Phase 1 open-label single-sequence cocktail drug-drug interaction study evaluating the effect of multiple-dose Lambda on the single-dose pharmacokinetics of the preferred CYP enzyme substrates and a preferred OATP1B1/OATP1B3 substrate administered to patients with chronic HDV infection |
EIP Pharma Inc. | Recruitment not yet started |
| 1006735 |
An Open-Label Randomized Three-Period Study in Healthy Subjects to Investigate the Effect of AZD5055 on the Pharmacokinetics of Nintedanib |
AstraZeneca AB | |
| 1006859 |
An International Prospective Open-label Multi-center Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) |
Novartis Pharma AG | |
| 1006875 |
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide Bortezomib Dexamethasone (PVd) or Carfilzomib Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy Including an Anti-CD38 Monoclonal Antibody and Lenalidomide |
Janssen-Cilag International N.V. | |
| 1006952 |
A Phase 2 Clinical Study of FMPV-1/GM-CSF in Addition to Standard of Care (SoC) Pembrolizumab in Patients with Metastatic MSI-H Colorectal Tumours with Particular Reference to TGFbR2 Frameshift Mutation |
Hubro Therapeutics AS | Recruitment not yet started |
| 1006973 |
A Phase 3 Randomized Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma |
BeiGene UK Ltd | |
| 1007001 |
A single arm open-label Phase 3b study to describe the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with IDH1m acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy |
Servier Affaires Medicales | |
| 1007040 |
Multi-center Randomized Double-blind Parallel-group Double-dummy Active-controlled Comparative Study to Evaluate the Efficacy Safety Pharmacokinetics and Pharmacodynamics of Ponesimod Versus Fingolimod During 108 Weeks of Treatment in Pediatric Participants 10 to <18 Years Old with Relapsing-remitting Multiple Sclerosis |
Janssen-Cilag International N.V. | Recruitment not yet started |
| 1007096 |
A Phase I Placebo- and Positive-controlled Crossover Study to Investigate the Effects of Tideglusib on QTc Interval in Healthy Subjects |
AMO Pharma Ltd | Recruitment not yet started |
| 1007113 |
An 18-month low-interventional prospective multicentre study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa |
IQVIA RDS AG | |
| 1007157 |
Encorafenib/Binimetinib Master Protocol: An Open-Label Continuation Study For Participants Continuing From Encorafenib/Binimetinib Clinical Studies |
Pfizer Inc. | |
| 1007196 |
An open-label multicenter phase I study evaluating the safety tolerability pharmacokineticspharmacodynamics and preliminary clinical activity of RO7428731 in participants with glioblastoma expressing mutant epidermal growth factor receptor variant III |
F. Hoffmann-La Roche AG | Recruitment not yet started |
| 1007203 |
A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients in Hepatorenal Syndrome – Acute Kidney Injury |
River 2 Renal Corp. | |
| 1007335 |
A Phase 2 randomized prospective partial double-blind placebo-controlled trial to evaluate the preliminary efficacy and safety of inhaled carbon monoxide upon kidney function in kidney transplant recipients |
Proterris (Portugal) LDA. | |
| 1007542 |
A Modular Open-Label Multi-Centre Phase 1/2 Dose-Finding Optimisation and Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer |
Ellipses Pharma Limited | |
| 1007686 |
ALB-TRIAL: Personalised long-term human albumin treatment in patients with decompensated cirrhosis and ascites |
Odense University Hospital | |
| 1007726 |
Minderoo 5G: A Next Generation AGile Genomically Guided Glioma Modular Platform for proof-of-concept molecular hypothesis testing in patients with high grade malignant brain tumours and 5G-PEARL: Paxalisib as monotherapy and in combination with Temozolomide in patients with high grade malignant brain tumours within the Minderoo 5G Platform |
The Institute of Cancer Research | |
| 1007826 |
A 2-part study consisting of an open-label multiple ascending dose (MAD) safety study and a dose-finding single-masked comparative safety and preliminary efficacy study of intravitreal (IVT) EYE103 in a mixed population of participants with diabetic macular oedema (DMO) and neovascular age-related macular degeneration (NVAMD) |
F. Hoffmann-La Roche AG | |
| 1007851 |
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979) an Anti-CD20x Anti-CD3 Bispecific Antibody Combined with Chemotherapy Versus Rituximab Combined with Chemotherapy in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-2) |
Regeneron Pharmaceuticals Inc. | |
| 1008010 |
A Phase III Open-Label Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma |
F. Hoffmann-La Roche AG | |
| 1008258 |
A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study with a Treatment and Observation Period to Evaluate the Safety and Efficacy of Vesleteplirsen (SRP-5051) in Ambulatory Subjects with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment (MOTIVATE) |
Sarepta Therapeutics Inc. | Recruitment not yet started |
| 1008314 |
A Phase 3 Multicenter Double-Blind Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age with Achondroplasia: PROPEL 3 |
QED Therapeutics Inc. | |
| 1008469 |
A multicenter randomized double-blind placebo-controlled 12-week study to evaluate the pharmacokinetics pharmacodynamics and safety of oral difelikefalin in subjects with advanced chronic kidney disease and moderate-to-severe pruritus with a 24-week open-label extension |
Cara Therapeutics Inc. | Recruitment not yet started |
| 1008610 |
Cambridge Centre for Myelin Repair Trial Three: a phase 2b randomised single-site double-blind placebo-controlled trial of the combination of six months of low-dose bexarotene and tamoxifen to promote remyelination in adults with relapse remitting multiple sclerosis stable on disease-modifying therapy |
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge |
Recruitment not yet started |
| 1008879 |
Pharmacokinetic (PK) study to investigate the pharmacokinetic profile of norucholic acid (NCA) in primary sclerosing cholangitis (PSC) patients treated with NCA capsules within open-label extension (OLE) NUC-5/PSC |
Dr Falk Pharma GmbH |